First Sales into the Federal Government

A contract vehicle or distributor listing merely makes a product orderable. It does not generate clinical demand, navigate facility gatekeepers, or perform the ground-level work required to achieve product adoption.

The First Sale Gap and Timeline Reality

Selling medical technology into the federal government is rarely a fast or direct extension of commercial sales. Even with FDA clearance, robust clinical data, and strong commercial traction, new manufacturers face a steep, multi-step entry process that takes time.

Achieving a first federal sale requires establishing agency relationships, securing compliant contract vehicles, navigating facility-level reviews, and setting up local distribution.

This creates a classic circular challenge. Traditional broadline distributors prefer products that already have established federal demand, active contract access, and recurring order volume.

They may accept a product into a catalog, but they rarely invest the field resources required to drive clinical promotion, engage facility stakeholders, or shepherd a device through complex administrative channels. Product availability alone does not equal product adoption.

Because building federal traction involves long lead times and complex administrative hurdles, emerging manufacturers benefit significantly from partnering with a trusted, specialized federal distributor.

An experienced partner brings pre-existing contract access, regulatory know-how, and dedicated field support to bridge the “first-sale gap,” helps shorten the onboarding timeline, and turns clinical interest into actionable orders.

Internal Review Is a Separate Gate

Securing a contract vehicle is only half the battle; internal facility review is an equal, time-consuming hurdle.

Depending on the agency and facility, a medical device must clear multidisciplinary evaluations from Value Analysis Committees (VACs), Clinical Product Review Committees (CPRCs), Pharmacy & Therapeutics (P&T) teams, Biomedical Engineering, and Cybersecurity reviewers.

These committees evaluate far more than simple clinical efficacy. They analyze equipment compatibility, workflow impact, staff training burdens, sterile processing protocols, infection control, cybersecurity, and supply chain reliability.

At Veterans Health Administration (VHA) facilities, formal clinical product review is mandatory for all new expendable supplies, reusable medical equipment, and instruments before first use.

A favorable conversation with a champion clinician is essential, but it does not bypass this rigorous internal vetting process.

Prepare for Adoption, Not Just Availability

To succeed, manufacturers must prepare for a structured, multi-stage adoption process rather than a quick sales pitch.

A complete, federal-ready submission package requires:

• Clinical safety and efficacy evidence
• Comparative cost and lifecycle-value analysis
• Cybersecurity documentation (MDS2, SBOM, network diagrams)
• Detailed implementation and staff training plans
• Supply-chain continuity and service commitments

Navigating these requirements requires ongoing management—tracking committee submissions, resolving action items, confirming compliant purchasing routes, managing quotes, coordinating delivery, and delivering post-sale clinical support.

Given the time, complexity, and specialized knowledge required to navigate federal healthcare, aligning with a trusted distribution partner provides the strategy, infrastructure, and patience needed to achieve long-term commercial success.